Adagrasib plus cetuximab fails to outperform chemotherapy in KRAS G12C-mutated metastatic colorectal cancer
The phase III KRYSTAL-10 trial did not meet its co-primary survival endpoints
Treatment duration of immunotherapy combination does not impact on disease-free survival in dMMR colon cancer
An ATOMIC study pre-planned exploratory analysis reports no DFS benefit with the addition of immunotherapy in patients receiving fewer than six cycles of chemotherapy
Novel data support the use of liquid biopsy to guide cetuximab rechallenge in metastatic colorectal cancer
Tumours with no ctDNA-identified pathogenic variants for anti-EGFR drug resistance genes appear to respond to continued cetuximab beyond disease progression
Exploiting HER2 tumour heterogeneity with digital oncology
Multi-regional modelling reveals new ways to personalise treatments in gastric and breast cancers
Optimal sequencing of immunotherapy in MSI-H/dMMR colon cancer remains uncertain
In light of recent evidence from the ATOMIC trial, balancing adjuvant and neoadjuvant immunotherapy approaches continues to challenge clinical decision-making.
Structured exercise enters ESMO guidelines for colon cancer as recommended treatment
The update reflects survival benefits of post-diagnosis exercise in stage II–III colon cancer as recently reported in the CHALLENGE study
Next-generation KRAS G12C inhibitor shows promising activity in advanced colorectal cancer
Manageable safety and encouraging antitumour responses were presented with MK-1084 monotherapy and combination regimens
Novel combination shows survival benefits in high-risk gastric/gastro-oesophageal junction cancer
Encouraging data were reported for SHR-1701 added to first-line CAPOX in a post-hoc analysis of patients with high-risk features from a Chinese study
ctDNA-guided adjuvant chemotherapy in colon cancer: not ready for prime time?
Two studies fail to meet their primary endpoints, reinforcing the need to improve the sensitivity of ctDNA testing before it enters the clinic
First-line bemarituzumab improves short-term survival in gastric or gastroesophageal junction cancer overexpressing FGFR2b
Positive initial overall survival data were, however, attenuated and may not be clinically meaningful in a longer-term analysis